The Contribution of the Pharmaceutical Industry to the Health Status of the developing World

Research output: Chapter in Book / Report / Conference proceedingChapterAcademicpeer-review

Abstract

There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.
Original languageEnglish
Title of host publicationMULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT
EditorsXiaolan Fu, Pervez N Ghauri, Juha Väätänen
Place of PublicationUnited Kingdom
PublisherEmerald Group Publishing Limited
Pages41
Number of pages67
Volume33
ISBN (Electronic)978-1-78743-163-8
ISBN (Print)978-1-78743-163-8
Publication statusPublished - 2017

Publication series

NameINTERNATIONAL BUSINESS & MANAGEMENT
PublisherEmerald
Volume33
ISSN (Print)1876-066X

Fingerprint

Pharmaceutical industry
Developing world
Medicine
Health status
Multinational enterprises
Pharmaceuticals
Income
Healthcare
Economic growth and development
Licensing
Expenditure
Technology transfer
Pricing strategy
Systematic review
Labor
International organizations
Proportion
Interaction
Productivity
Functionality

Cite this

Muniz Pereira Urias, E. (2017). The Contribution of the Pharmaceutical Industry to the Health Status of the developing World. In X. Fu, P. N. Ghauri, & J. Väätänen (Eds.), MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT (Vol. 33, pp. 41). (INTERNATIONAL BUSINESS & MANAGEMENT; Vol. 33). United Kingdom: Emerald Group Publishing Limited.
Muniz Pereira Urias, E. / The Contribution of the Pharmaceutical Industry to the Health Status of the developing World. MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT. editor / Xiaolan Fu ; Pervez N Ghauri ; Juha Väätänen. Vol. 33 United Kingdom : Emerald Group Publishing Limited, 2017. pp. 41 (INTERNATIONAL BUSINESS & MANAGEMENT).
@inbook{70879a3c655742b091d80539f4c0e9a1,
title = "The Contribution of the Pharmaceutical Industry to the Health Status of the developing World",
abstract = "There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.",
author = "{Muniz Pereira Urias}, E.",
year = "2017",
language = "English",
isbn = "978-1-78743-163-8",
volume = "33",
series = "INTERNATIONAL BUSINESS & MANAGEMENT",
publisher = "Emerald Group Publishing Limited",
pages = "41",
editor = "Xiaolan Fu and Ghauri, {Pervez N} and Juha V{\"a}{\"a}t{\"a}nen",
booktitle = "MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT",

}

Muniz Pereira Urias, E 2017, The Contribution of the Pharmaceutical Industry to the Health Status of the developing World. in X Fu, PN Ghauri & J Väätänen (eds), MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT. vol. 33, INTERNATIONAL BUSINESS & MANAGEMENT, vol. 33, Emerald Group Publishing Limited, United Kingdom, pp. 41.

The Contribution of the Pharmaceutical Industry to the Health Status of the developing World. / Muniz Pereira Urias, E.

MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT. ed. / Xiaolan Fu; Pervez N Ghauri; Juha Väätänen. Vol. 33 United Kingdom : Emerald Group Publishing Limited, 2017. p. 41 (INTERNATIONAL BUSINESS & MANAGEMENT; Vol. 33).

Research output: Chapter in Book / Report / Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - The Contribution of the Pharmaceutical Industry to the Health Status of the developing World

AU - Muniz Pereira Urias, E.

PY - 2017

Y1 - 2017

N2 - There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.

AB - There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.

M3 - Chapter

SN - 978-1-78743-163-8

VL - 33

T3 - INTERNATIONAL BUSINESS & MANAGEMENT

SP - 41

BT - MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT

A2 - Fu, Xiaolan

A2 - Ghauri, Pervez N

A2 - Väätänen, Juha

PB - Emerald Group Publishing Limited

CY - United Kingdom

ER -

Muniz Pereira Urias E. The Contribution of the Pharmaceutical Industry to the Health Status of the developing World. In Fu X, Ghauri PN, Väätänen J, editors, MULTINATIONAL ENTERPRISES AND SUSTAINABLE DEVELOPMENT. Vol. 33. United Kingdom: Emerald Group Publishing Limited. 2017. p. 41. (INTERNATIONAL BUSINESS & MANAGEMENT).